Early-stage study of Advaxis' cancer candidate ADXS-NEO underway [Seeking Alpha]
Advaxis, Inc. (ADXS)
Last advaxis, inc. earnings: 9/9 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.advaxis.com
Company Research
Source: Seeking Alpha
Early-stage study of Advaxis' cancer candidate ADXS-NEO underwayThe first patient has beendosed in aPhase 1 clinical trial assessing Advaxis' (ADXS) ADXS-NEO, a personalized immunotherapy targeting cancer neoantigens, in patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.Participants will undergo a biopsy. Advaxis will then manufacture a customized treatment based on an analysis of their tumor neoantigen mutations, a process that takes ~eight weeks.According to ClinicalTrials.gov, the estimated primary completion date is September 2019.The company is co-developing ADXS-NEO with Amgen (AMGN-0.6%), with Advaxis leading development through proof-of-concept.Click to subscribe to real-time analytics on ADXSNow read:Has A New Advaxis Awakened Out Of The Doldrums? »
Show less
Read more
Impact Snapshot
Event Time:
ADXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXS alerts
High impacting Advaxis, Inc. news events
Weekly update
A roundup of the hottest topics
ADXS
News
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ADXS
Sec Filings
- 4/19/24 - Form 8-K/A
- 4/16/24 - Form 10-K
- 4/15/24 - Form S-8
- ADXS's page on the SEC website